Trials / Completed
CompletedNCT00345735
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients. A Randomised, Double-blind, Placebo-controlled, Cross-over Confirmatory Trial Testing Fentanyl and Placebo in Eight Breakthrough Pain Episodes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Nycomed · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To demonstrate the efficacy of intranasal fentanyl in the treatment of breakthrough pain (BTP) in cancer patients. Secondary Objective: To explore the relationship between the response to the fentanyl dose and the stable background pain opioid dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fentanyl |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-06-28
- Last updated
- 2012-05-07
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00345735. Inclusion in this directory is not an endorsement.